16.97

1.00% 0.1547

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $16.97, with a volume of 442.36K. It is up +1.00% in the last 24 hours and up +3.53% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Previous Close:

$16.82

Open:

$16.58

24h Volume:

442.36K

Relative Volume:

0.55

Market Cap:

$1.53B

Revenue:

Net Income/Loss:

$-249.31M

P/E Ratio:

-5.1283

EPS:

-3.31

Net Cash Flow:

$-209.70M

1W Performance:

-2.08%

1M Performance:

+3.53%

6M Performance:

-27.62%

1Y Performance:

-19.02%

1-Day Range:

$16.12

$17.00

1-Week Range:

$16.12

$17.42

52-Week Range:

$15.97

$32.52

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

268

Twitter

@rocketpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

RCKT's Discussions on Twitter

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

05:22 AM

Harbor Capital Advisors Inc. Has $3.11 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat

05:22 AM

Nov 04, 2024

Rocket Pharmaceuticals executive sells $51,205 in common stock - Investing.com

Nov 04, 2024

Rocket Pharmaceuticals executive sells $51,205 in common stock By Investing.com - Investing.com UK

Nov 04, 2024

Nov 03, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Oct 22, 2024

Oct 21, 2024

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.3%Here's What Happened - MarketBeat

Oct 21, 2024

Oct 18, 2024

Fanconi Anemia Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | Foresee Pharma, Rocket Pharma, John Diaz, Novartis, Sierra Oncology - The Globe and Mail

Oct 18, 2024

Oct 17, 2024

Scotiabank Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Sector Outperform Recommendation - MSN

Oct 17, 2024

Oct 16, 2024

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpWhat's Next? - MarketBeat

Oct 16, 2024

Investors in cash trouble should check out Rocket Pharmaceuticals Inc (RCKT) - SETE News

Oct 16, 2024

Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Scotiabank - MarketBeat

Oct 16, 2024

Oct 15, 2024

The Attractiveness of Investing In Rocket Pharmaceuticals Inc (RCKT) is Growing - Knox Daily

Oct 15, 2024